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Table 1. Frequency of AD Risk Alleles Is Higher in
Unaffected Individuals from Multiply Affected Families
Than in Unrelated Controls
Locus and Allele
No. (%) of Subjects
Cases Controls
Linkage CC Linkage CC
APOE:
2 7 (2.3) 80 (4.2) 16 (5.2) 181 (8.5)
3 169 (54.9) 1,144 (60.2) 197 (64.4) 1,691 (79)
4 (Risk allele) 132 (42.8) 676 (35.6) 93 (30.4) 268 (12.5)
rs498055:
A 133 (46.2) 915 (47.9) 140 (46.4) 1,174 (54.4)
G (Risk allele) 155 (53.8) 995 (52.1) 162 (53.6) 984 (45.6)
NOTE.—CCp case-control study.
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Reply to Bertram et al.
To the Editor: The study by Bertram and colleagues (in
this issue)1 failed to replicate, in two family-based sample
sets, the association of rs498055 with Alzheimer disease
(AD [MIM 104300]) that we observed in four large, well-
characterized case-control sample sets.2 Although the re-
sult is disappointing, there are several differences between
the studies that may have contributed to these discrepant
findings. First, there are significant differences in the study
designs. Bertram et al. used two family-based sample sets
that included subjects with both early- and late-onset
AD (e.g., 320 families with late-onset AD and 117 families
with early/mixed-onset in the National Institute ofMental
Health [NIMH] sample set) of different ethnicities (94%
white; 6% others),3 which resulted in 147 informative
families with late-onset AD for both sample sets com-
bined. The characterization of their unaffected controls
was based on self-assessment or a telephone interview, a
procedure sufficient when “unaffecteds” are used solely
to determine phase in linkage studies, but likely to sig-
nificantly impact power in association studies, especially
when familial loading is high, as it is in the sample of
Bertram et al. Indeed, the authors acknowledge this in one
of their previous publications by pointing out that the
characterization of controls “may miss some mild cases of
dementia” and lead “to a decrease in power.”3 In contrast,
our study included only clinically evaluated, late-onset
cases and nondemented controls of white origin. Second,
the use of a family-based sample that was ascertained on
the basis of multiple affected relatives is likely to partic-
ularly adversely impact power to detect a risk allele of
relatively high frequency and small effect size, such as
rs498055. Under these circumstances, the allele frequency
in unaffected relatives also increases,4 with consequent
loss of power in comparisonwith case-control studies such
as our own. To investigate this more fully, we compared
the allele frequencies for a known genetic risk factor for
AD, apolipoprotein E (APOE [MIM 107741]), and for the
putative risk factor under debate, rs498055, in our com-
bined case-control series and in the NIMH linkage families
used by us in the study described by Myers et al.5 In this
context, it is worth noting that 355 of 372 individuals
from the linkage sample–derived cases in our recent pub-
lication overlap with affected individuals in the NIMH
family sample set described by Bertram et al. For the com-
parison, we identified the subgroup of NIMH families with
genotypes for at least one unaffected and one affected
individual and then selected at random one unaffected
and one affected individual from each of these families.
Table 1 illustrates clearly that the frequency of the APOE4
allele is substantially higher in unaffected individuals from
the linkage families than in unaffected individuals from
the case-control series (30.4% vs. 12.5%) and that, although
the APOE4 allele frequency is highest in the linkage cases,
the difference between the unrelated cases and controls
is much greater than that between familial cases and re-
lated controls (35.6% vs. 12.5% compared with 42.8% vs.
30.4%). As a result, the odds ratio (OR) for theAPOE4 allele
in the case-control series is 3.8, compared with only 1.7
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Table 1. LD between SERPINE2 SNPs Expressed as r2
SNP
r2 for SNP
rs1438831 rs920251 rs6747096a rs3795879
rs920251 .952 (1.0) … … …
rs6747096a .140 .148 … …
rs3795879a .140 (.145) .145 (.145) .964 …
ss49785625a .020 .023 .054 .055
NOTE.—The r2 values in parentheses are values obtained from HapMap
and compared with our own data in controls. ss49785625 and rs6747096
are not in HapMap.
a SNP reported by DeMeo et al.1 to be associated with disease in both
family and case-control cohorts.
for the family-based samples. Similarly for rs498055, the
difference in frequencies between the cases and controls
is greater for the unrelated samples than for the linkage
families (table 1). Thus, the failure of Bertram et al. to
replicate our results does not necessarily indicate that the
original association was a false-positive result. We concur
with Bertram et al. that the significant association of
rs498055 in four of six samples “may be unlikely to occur
by chance”1(p181) (in this issue). However, it is possible that
our initial study provided an overestimate of the allelic
OR for rs498055. If this were true and the OR were !1.3,
then the study by Bertram et al. would clearly be under-
powered. Further replication in well-characterized sample
sets is required to assess whether the association is gen-
uine. Ideally, this should be done with large case-control
sample sets, to achieve maximum power. For this partic-
ular marker, we estimate that 360 cases and 360 controls
are needed to achieve 80% power in a replication study
(one-sided ), assuming an allelic OR of 1.3 andap .05
a risk-allele frequency of 45.6%. A meta-analysis of all
studies should then be performed to determine whether
rs498055 is associated with late-onset AD. In addition, it
might be interesting to test the other reported significant
markers from this region in additional sample sets.
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The SERPINE2 Gene and Chronic Obstructive
Pulmonary Disease
To the Editor: In the February 2006 issue of the Journal,
DeMeo et al.1 identified SERPINE2 as a positional candi-
date gene for susceptibility to chronic obstructive pul-
monary disease (COPD [MIM 606963]) and reported on
the association of polymorphic variants of this gene with
early-onset disease in a family-based study andwith severe
disease in a case-control study. With early prior infor-
mation provided by the authors, we have independently
tested for an association of the SERPINE2 gene with COPD
in the largest case-control study reported to date. Our
study consists of 1,018 COPD cases and 911 controls pro-
spectively recruited from six European centers. We have
provided details about the patients elsewhere.2 The study
population was screened for genotypes at the Medical Re-
search Council (United Kingdom) Gene Services Unit for
five SNPs (table 1) in the SERPINE2 gene. All the SNPs
evaluated were reported in the study by DeMeo et al. as
associated with disease, with three of the five associated
with disease in both the family and case-control study
cohorts they assessed.
